Kate Klimczak appointed president of ACT for NIH, Richard Turman steps down

Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel

Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, said he was named chair of the President’s Cancer Panel. Risch will succeed Elizabeth M. Jaffee, who was appointed by President Joe Biden in January 2023.

Renuka Iyer named chief medical officer for NCCN

Renuka Iyer was appointed chief medical officer for the National Comprehensive Cancer Network—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care.

December 12, 2025

Vol.51 No.45

In Brief

Wafik El-Deiry re-elected chair of WIN Consortium; SWOG joins WIN

Wafik S. El-Deiry was re-elected as the chair of the WIN Consortium in Precision Oncology.

December 12, 2025

Vol.51 No.45

In Brief

Robin Toft named CEO of Curebound

Robin Toft was appointed CEO of Curebound, a philanthropic organization that fundraises for and invests in cancer research, effective Jan. 1.

December 12, 2025

Vol.51 No.45

NCI

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

FDA issued a draft guidance on Dec. 2, outlining specific product types for which the FDA believes six-month non-human primate toxicity testing can be eliminated or reduced.

December 05, 2025

Vol.51 No.44

By Jacquelyn Cobb

Kate Klimczak appointed president of ACT for NIH, Richard Turman steps down

YOU MAY BE INTERESTED IN

Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel

Renuka Iyer named chief medical officer for NCCN

Wafik El-Deiry re-elected chair of WIN Consortium; SWOG joins WIN

Robin Toft named CEO of Curebound

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

FDA releases draft guidance on reducing testing on non-human primates for monoclonal antibodies

Renew today!

Subscriber content

Never miss an issue!

Login